Report of Foreign Issuer (6-k)
24 September 2016 - 12:57AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
September 23, 2016
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk submits application in the
US for including data from the two SWITCH trials in Tresiba
®
label
Bagsværd, Denmark, 23 September 2016
– Novo Nordisk
today announced the submission of a supplemental application to the US Food and Drug Administration (FDA) for including data from
the two SWITCH phase 3b trials in the label for Tresiba
®
.
In SWITCH 1, people with type 1 diabetes were randomised to cross-over
treatment with Tresiba
®
and insulin glargine U100, respectively, both in combination with
insulin aspart. During the study’s maintenance period, people treated with Tresiba
®
on average had 11% fewer episodes of overall symptomatic blood glucose confirmed hypoglycaemia, 36% fewer episodes of nocturnal
blood glucose confirmed symptomatic hypoglycaemia and 35% fewer episodes of severe hypoglycaemia. All of the above results were
statistically significant and similar results were seen in the full treatment period.
In SWITCH 2, people with type 2 diabetes were randomised to cross-over
treatment with Tresiba
®
and insulin glargine U100, respectively, both in combination with
oral antidiabetic drugs. During the study’s maintenance period, people treated with Tresiba
®
on average had 30% fewer episodes of overall blood glucose confirmed symptomatic hypoglycaemia and 42% fewer episodes of nocturnal
blood glucose confirmed symptomatic hypoglycaemia, both favouring Tresiba
®
over insulin
glargine U100. Both observations were statistically significant and similar results were observed for the full treatment period.
For severe hypoglycaemia there was a 46%, but not statistically significant reduction of the episodes in the maintenance period,
and a statistically significant 51% reduction of the episodes in the full treatment period for Tresiba
®
compared to insulin glargine U100.
In both studies, the mean baseline for HbA
1c
was 7.6%, and both studies showed that Tresiba
®
was non-inferior in terms of HbA
1c
reduction compared to insulin glargine U100. This means that the requirements for objectively comparing hypoglycaemia episodes
between the two treatments were fulfilled. In both studies, Tresiba
®
generally appeared
to have a safe and well-tolerated profile.
“Hypoglycaemia
continues to be a real challenge for many people with
type 1 and type 2 diabetes. We believe that inclusion of the SWITCH trial results in the prescribing information for Tresiba®
will provide healthcare professionals with important information
Page 2 of 2
to make an informed choice when prescribing basal insulin” said
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
About Tresiba
®
Tresiba
®
(insulin degludec) is
a once-daily basal insulin that provides a duration of action beyond 42 hours. It is important for people with type 1 and type
2 diabetes to establish a routine for insulin treatment. Tresiba
®
is taken once daily,
at any time of day. Patients who miss or are delayed in taking their dose of Tresiba
®
can take their dose as soon as they remember, making sure there are at least eight hours between doses. Tresiba
®
received its first regulatory approval in September 2012 and has since been approved in more than 70 countries globally. It was
approved by the FDA in the United States on 25 September 2015.
About SWITCH 1 and 2
The two phase 3b, 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials were initiated
in January 2014 to compare the safety profile and efficacy of Tresiba
® and insulin glargine U100.
In the trials, people were treated for a 16-week titration period followed by a 16-week maintenance period and subsequently switched
to the comparator drug. The overall objective was to document the hypoglycaemia profile in type 1 diabetes and type 2 diabetes,
respectively. In SWITCH 1, 501 people with type 1 diabetes were randomised to cross-over treatment with Tresiba® and insulin
glargine U100 in combination with insulin aspart. In SWITCH 2, 721 people with type 2 diabetes were randomised to cross-over treatment
with Tresiba® and insulin glargine U100 in combination with oral antidiabetic drugs.
Novo Nordisk is a global healthcare
company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities
that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered
in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For
more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Katrine Sperling
|
+45 4442 6718
|
krsp@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 786 8316
|
kiau@novonordisk.com
|
|
|
|
Investors
:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Hanna Ögren
|
+45 3079 8519
|
haoe@novonordisk.com
|
Kasper Veje (US)
|
+1 609 235 8567
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 64 / 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: September 23, 2016
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2024 to May 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From May 2023 to May 2024